1. Rosiglitazone as an option for patients with acromegaly: a case series
- Author
-
María Dolores Gómez de Ossio, Alejandra Lorena Tamez-Peña, Hugo Gutiérrez-Hermosillo, Héctor E Tamez-Pérez, and Ana Bahena-García
- Subjects
Medicine(all) ,medicine.medical_specialty ,business.industry ,Growth factor ,medicine.medical_treatment ,lcsh:R ,lcsh:Medicine ,Case Report ,General Medicine ,medicine.disease ,Growth hormone secretion ,Basal (phylogenetics) ,Endocrinology ,Pharmacotherapy ,Surgical oncology ,Internal medicine ,Growth hormone overproduction ,Acromegaly ,medicine ,Rosiglitazone ,business ,medicine.drug - Abstract
Introduction In the patient with acromegaly, pituitary surgery is the therapeutic standard. Despite undergoing surgery, a significant number of patients with acromegaly continue to have uncontrolled growth hormone secretion. These patients require other treatments such as external irradiation and/or drug therapy. Case presentation We present the clinical and laboratory responses to six months of treatment with rosiglitazone in four cases. In all four cases, the patients had persistent growth hormone overproduction despite previous surgical treatment and other conventional therapy. Case 1 is a 57-year-old Caucasian woman, case 2 is a 51-year-old Hispanic man, case 3 is a 32-year-old Hispanic woman, and case 4 is a 36-year-old Hispanic man. In three of these patients, basal and nadir growth hormone and insulin-like growth factor 1 levels were significantly decreased (P < 0.05 and P < 0.01, respectively). Conclusion Rosiglitazone could be a treatment option in select patients with acromegaly.
- Published
- 2011